Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 4/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655078 | 0.91 | MAPT (0.70) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL23494034 | 0.90 | MAPT (0.74) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL31307855 | 0.90 | MAPT (0.74) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL3787191 | 0.89 | MAPT (0.74) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL403264 | 0.89 | AURKB (0.67) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL18998183 | 0.89 | AURKB (0.75) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL30864147 | 0.89 | AURKB (0.75) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL3782288 | 0.88 | MAPK1 (0.63) | MAPTAURKBAURKAGAASMN1; SMN2 | |
| SCHEMBL5327687 | 0.88 | PAX8 (0.81) | MAPTGAASMN1; SMN2THRBMEN1 | |
| SCHEMBL31307883 | 0.88 | PAX8 (0.81) | MAPTGAASMN1; SMN2THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220047-B1 | Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof | CLANOTECH AB (SE) | 2015-05-06 | — | — | EP | disclosed |
| US-8957092-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2015-02-17 | — | — | US | disclosed |
| US-8957092-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2015-02-17 | — | — | US | disclosed |
| US-8957092-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2015-02-17 | — | — | US | disclosed |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANO TECH AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANO TECH AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANO TECH AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8557843-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2013-10-15 | — | — | US | disclosed |
| US-8557843-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2013-10-15 | — | — | US | disclosed |
| US-8557843-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2013-10-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2220047-A2 | COMPOUNDS AND METHODS | ClanoTech AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063070-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008119771-A2 | QUINOLINE-S-CARBOXYLIC ACID DERIVATIVES AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119771-A2 | QUINOLINE-S-CARBOXYLIC ACID DERIVATIVES AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BRAF, MAP3K1, MAP3K7 | MAPT 253/4885AURKB 302/4885AURKA 449/4885 |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BRAF, TYK2, MAP3K6 | MAPT 297/4885AURKB 150/4885AURKA 228/4885 |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | FLT1, FLT4, VEGFA | MAPT 231/4885AURKB 1311/4885AURKA 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.